USANA Health Sciences (NYSE:USNA) Upgraded at Zacks Research

Key Points

• Zacks Research upgraded USANA Health Sciences from “strong sell” to “hold,” but the broader analyst consensus remains “Reduce,” with one Hold and one Sell rating.
• USANA reported a quarterly loss of $0.07 per share, missing the $0.43 consensus estimate, while revenue of $223.27 million also fell short of expectations.
• The stock opened at $14.91, near the lower end of its 52-week range of $12.57 to $26.76; institutional investors own approximately 54.25% of the company.

USANA Health Sciences (NYSE:USNA - Get Free Report) was upgraded by research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued to investors on Monday, Zacks reports.

A number of other research firms have also weighed in on USNA. Weiss Ratings reissued a "sell (d)" rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Wall Street Zen lowered USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, USANA Health Sciences has a consensus rating of "Reduce".

USANA Health Sciences Stock Performance

USNA opened at $14.91 on Monday. The company has a market cap of $275.61 million, a PE ratio of -12.33, a price-to-earnings-growth ratio of 1.63 and a beta of 0.68. The stock has a 50-day moving average of $15.15 and a 200-day moving average of $17.85. USANA Health Sciences has a 52-week low of $12.57 and a 52-week high of $26.76.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.The company had revenue of $223.27 million for the quarter, compared to the consensus estimate of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. On average, research analysts predict that USANA Health Sciences will post 0.76 earnings per share for the current year.

Institutional Trading of USANA Health Sciences

Large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in USANA Health Sciences in the second quarter valued at about $33,182,000. Pzena Investment Management LLC acquired a new stake in shares of USANA Health Sciences during the second quarter worth approximately $25,739,000. Nantahala Capital Management LLC bought a new position in shares of USANA Health Sciences in the second quarter valued at approximately $17,295,080. Algert Global LLC raised its stake in shares of USANA Health Sciences by 91.8% in the second quarter. Algert Global LLC now owns 131,758 shares of the company's stock valued at $2,813,000 after acquiring an additional 63,074 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of USANA Health Sciences in the 2nd quarter worth approximately $1,500,000. 54.25% of the stock is currently owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops and sells nutritional supplements, personal-care products and foods designed to support general health and wellness. Its product portfolio includes vitamins and mineral supplements, herbal and specialty nutritional products, meal-replacement and snack items, and skincare products marketed under the USANA and Sensé brands.

Founded in 1992 by immunologist Myron Wentz, USANA distributes its products primarily through a direct-selling model involving independent associates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.